Gemtesa (Vibegron) Patent Expiration, LOE Window & CMS Spending

Gemtesa (Vibegron) by Sumitomo America: FDA Orange Book core substance LOE 2034-12-23 (last listed 2042-07-06), 0 AB generics, $981.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSumitomo America
FDA Application & PathwayN213006 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-12-23
Last Listed Patent or Exclusivity Date2042-07-06
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$981.7M
2024 Medicare Part D Spend$945.1M
2024 Medicaid Spend$36.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.